BOSTON--(BUSINESS WIRE)--Today Obagi Medical Products, Inc. (Nasdaq:OMPI), the leader in topical aesthetic and therapeutic skin health systems, announced the successful completion of a 12-week study comparing CLENZIderm M.D.TM Serum Gel to a leading combination prescription benzoyl peroxide (BPO)/clindamycin product. The announcement was made at the American Academy of Dermatology’s (AAD) Summer Academy Meeting in Boston, MA. Of the 65 enrolled patients, 23 received four weeks of treatment (100 percent compliance) and 42 received 12 weeks of treatment (88 percent compliance). The data of the multicenter, investigator-blind, randomized, split-face study shows that patients with moderate facial acne vulgaris experienced significantly greater reductions in non-inflammatory lesions when using the CLENZIderm M.D. Serum Gel when compared to the leading topical BPO/clindamycin product.
